Rather than discussing mainly structural aspects of the ubiquitin system, this conference is dedicated to the study of functional roles of the ubiquitin system, how it works to ensure normal signal transduction, what are the pathological consequences when it is perturbed and how can we harness our knowledge of the ubiquitin system therapeutically for more efficacious treatment of diseases with high unmet clinical need, including cancer, chronic inflammatory and autoimmune disorders as well as neurodegenerative diseases.
Importantly, this conference aims to become the go-to forum at which the most current and up-to-date therapeutic avenues that emerge from the study of the ubiquitin system will be presented and discussed.
Vishva Dixit, one of the organisers, says ‘The field of ubiquitin biology and applications to clinical medicine is one of the most exciting topics in Biomedicine. With the realization that widely prescribed powerful immunomodulatory drugs (IMIDs) including thalidomide and its analogues lenalidomide and pomalidomide work by engaging ubiquitin mediated degradation of critical targets, the field has exploded. A PROTAC strategy (Proteolysis targeting chimera) is now underway at all major Biopharma enterprises to extend the lessons from the IMID field to specifically target unwanted proteins. The impact of the field is far reaching. Indeed, the Nobel Prize this year was given to researchers who worked out how hypoxia engages the ubiquitin system to regulate oxygen availability. The future for the field has never been brighter. Clear your calendars and come join what should be a most exciting conference. It will focus on the myriad ways ubiquitin controls the signaling circuitry of life. If the regulation exerted by ubiquitin goes awry the consequences are devastating: it promulgates the pathology associated with inflammatory disease states, cancer and neurodegeneration.’